Appears On
Episode Appearances
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
“Discussed Maritide's improved tolerability and less frequent dosing as next-gen obesity treatment advantages”
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomes
View Analysis